A little over a week ago, GSK Velu occupied centre stage at an event in New Delhi. Neuberg Diagnostics, Velu’s two-year-old diagnostics venture, was entering into a strategic partnership with the Centre for Cellular And Molecular Platforms (C-CAMP), an initiative of the Ministry of Science and Technology and Earth Sciences. 

Among other things, the memorandum of agreement signed at the event would give Neuberg access to C-CAMP’s high-end technology, like electron microscopy. And while the C-CAMP partnership is largely for research purposes, it is yet another statement of intent from the young and hungry company.

Neuberg’s genesis in itself is fascinating. In 2015, when Velu exited Metropolis, the diagnostics giant he co-founded, most thought it was the end of his journey in the pathology lab industry. And with good reason. Velu, who sold his stake in Metropolis to PE firm Carlyle for Rs 900 crore ($127 million), has many other irons in the healthcare fire. 

Trivitron Healthcare, Velu’s medical device manufacturing business, for instance, clocked revenues of Rs 650 crore ($92 million) in the year ended March 2018. Trivitron also has a joint venture with the listed Apollo Hospitals—Alliance Medicorp—which operates both Apollo Dialysis and Apollo Dental, which has over 80 clinics. Velu serves as director of both businesses. There’s also Maxivision, a chain of eyecare hospitals, where he is both founder and chairman.

But return he did. And how. Velu’s re-entry into diagnostics in 2017—some two years after he left—has been nothing short of stellar. Neuberg, the veteran entrepreneur’s comeback vehicle, has grown at a pace never seen before in Indian diagnostics. In just two years, the company managed to clock revenues of Rs 450 crore ($64 million) in the year ended March 2019—its first full year of operations.

From out of nowhere, it is now the fourth largest player in terms of revenue in India’s pathology lab ecosystem. “Being rated as possibly the second largest startup in India just after Reliance Jio with Rs 450 crore in revenue in the first [full] year of operation and targeting over Rs 1,000 crore ($141 million) revenue within three to four years of operations… We could not have asked for anything better,” Velu said in an emailed response to The Ken.

Neuberg’s rise surprised many who thought the space was crowded enough as it is. While the opportunity is huge, with the Indian diagnostics space valued at $4 billion by brokerage firm Edelweiss and growing at 27.5% annually, it is dominated by a raft of large competitors. Dr Lal Path Labs, SRL Diagnostics, Metropolis and Thyrocare all have a pan-India presence.

What's in a name?


Suraksha P

Suraksha writes on Healthcare and Pharma. She has been a journalist for five years, reporting for The New Indian Express in Bengaluru and Chennai, and The Times of India, Delhi. In her previous stints she has written on health, civic issues and education. She investigated cover up of corruption in the state health department’s think tank, narrated harrowing tales of women who underwent unwarranted hysterectomies, and wrote about how loss of biometrics came in the way of Leprosy patients getting an Aadhaar card and thereby pension. She can be reached at suraksha at the-ken dot com.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.